Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.23 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
66 67 Next >
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
From Bristol Myers Squibb
Via Business Wire
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Check Out What Whales Are Doing With BMY
Via Benzinga
Why NYSE:BMY is a Top Pick for Dividend Investors.
Is BRISTOL-MYERS SQUIBB CO (NYSE:BMY) a Good Fit for Dividend Investing? 
Via Chartmill
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb
Via Benzinga
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
Via Benzinga
Europe Approves Bristol Myers Squibb's CAR-T Therapy For Early Treatment Of Type Of Blood Cancer
The European Commission approved Bristol Myers Squibb's Abecma for relapsed/refractory multiple myeloma, making it the first CAR T cell therapy endorsed in the EU for earlier treatment lines. 
Via Benzinga
Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual... 
Via Benzinga
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel 
Via MarketBeat
Exposures Product Safety
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer... 
Via Benzinga
Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign
From Bristol Myers Squibb
Via Business Wire
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &... 
Via Benzinga
Exposures Product Safety
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
From Bristol Myers Squibb
Via Business Wire
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
From Bristol Myers Squibb
Via Business Wire
Bristol Myers' Breyanzi Scores Second FDA Approval For Blood Cancers Therapy
FDA grants accelerated approval to Bristol Myers Squibb's Breyanzi, a CAR T cell therapy for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after two prior lines of... 
Via Benzinga
Exposures Product Safety
What's Going On With Cancer Focused-Geron Stock On Friday?
Geron sees lower share price with high volume. FDA committee votes favorably on imetelstat for transfusion-dependent anemia in adult MDS patients. June 16, 2024, set as FDA target action date.... 
Via Benzinga
Exposures Product Safety
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
From Bristol Myers Squibb
Via Business Wire
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into... 
Via Benzinga
Exposures Product Safety
Be A Smart Investor – Don’t Hold On For Dear Life
You have to give credit where it’s due. The bulls have been relentless for almost 18 months, but certainly over the past 5 months. 
Via Talk Markets
Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024
From Bristol Myers Squibb
Via Business Wire
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
Via Benzinga
U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,... 
Via Benzinga
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
Millionaire’s Blueprint: 7 Must-Have Stocks for Your Road to Wealthy Town
Discover must-have stocks for wealth for every investor, from healthcare and communication giants to financial and industrial sectors. 
Via InvestorPlace
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.